Table of Contents
Hull University Teaching Hospitals NHS Trust - Nuclear Medicine
Uncontrolled if printed
| SOP Code | Title | Review Date |
|---|---|---|
| REF006 | Cardiac Amyloidosis Imaging Referral Criteria | 2027-07-08 |
| Authorised By | Authorising Role | Authorisation Signature (only on master paper copy) | Date Authorised |
|---|---|---|---|
| Dr I Sunderji | ARSAC Licence Holder | 2024-07-08 |
REF006 - Cardiac Amyloidosis Imaging Referral Criteria
See REF000 - Referring to Nuclear Medicine (HUTH) for details of how to refer.
Description
Myocardial uptake of the radiotracer Technetium-99m-DPD has been validated and increasingly used in the non-biopsy diagnostic pathway of transthyretin related cardiac amyloidosis (ATTR). It offers a highly sensitive tool for detecting this disease and plays a key role in the non-invasive diagnostic workup of these patients[1]. However, it should be noted that DPD imaging is neither a primary tool to diagnose amyloid cardiomyopathy nor a tool to exclude cardiac amyloidosis on its own.
| ARSAC Licence Holders | Indication |
|---|---|
| Prof Stephen Richard Underwood | cardiac amyloid imaging |
| Dr Imran Sunderji | cardiac amyloid imaging |
| Radiopharmaceutical | CT component of SPECT/CT | |
|---|---|---|
| Typical Radiation Dose (mSv) | 5.6 | 0.5 |
Staff Entitled to Refer
All UK registered practitioners
Supplementary Drugs
Sodium chloride for parenteral use (0.9% w/v).
Contraindications
Pregnancy
